Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation via the E2F3-dependent mechanism.
机构:[1]Research Center for Integrated Medicine and Department of Nephrology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.[2]Department of Medicine and Therapeutics, and Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong, 999077, China.[3]Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, China.[4]State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China.[5]Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524001, China.[6]National Traditional Chinese Medicine Clinical Research Base, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.[7]CUHK-Guangdong Provincial People’s Hospital Joint Research Laboratory on Immunological and Genetic Kidney Diseases, the Chinese University of Hong Kong, Hong Kong, 999077, China.
This study was supported by grants from
Research Grants Council of Hong Kong (GRF
14163317, 14117418, 14104019, R4012-18); the Health
and Medical Research Fund of Hong Kong (HMRF
14152321, 05161326, 06173986, 07180516); the Lui Che
Woo Institute of Innovative Medicine (CARE
program); the Guangdong-Hong Kong-Macao-Joint
Labs Program from Guangdong Science and
Technology Department (2019B121205005); the
Luzhou Municipal‐Southwest Medical University
Joint Special Grant for the High‐level Talents
(Hui-Yao Lan Team and Chen Team); the Luzhou
Municipal‐Southwest Medical University Joint grant
(2020LZXNYDJ15); the research grant of Southwest
Medical University (2019ZZD010) and the basic
research platform grant of Luzhou
(2018LZXNYD-PT03).
第一作者机构:[1]Research Center for Integrated Medicine and Department of Nephrology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.[2]Department of Medicine and Therapeutics, and Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong, 999077, China.
通讯作者:
通讯机构:[2]Department of Medicine and Therapeutics, and Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong, 999077, China.[7]CUHK-Guangdong Provincial People’s Hospital Joint Research Laboratory on Immunological and Genetic Kidney Diseases, the Chinese University of Hong Kong, Hong Kong, 999077, China.[*1]Li Ka Shing Institute of Health Sciences, the Prince of Wales Hospital, Shatin, Hong Kong SAR, China. Address: Prince of Wales Hospital, Shatin, N.T. Hong Kong SAR, China.
推荐引用方式(GB/T 7714):
Wang Hong Lian,Wei Biao,He Hui Jun,et al.Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation via the E2F3-dependent mechanism.[J].THERANOSTICS.2022,12(1):379-395.doi:10.7150/thno.67034.
APA:
Wang Hong Lian,Wei Biao,He Hui Jun,Huang Xiao Ru,Sheng Jing Yi...&Lan Hui Yao.(2022).Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation via the E2F3-dependent mechanism..THERANOSTICS,12,(1)
MLA:
Wang Hong Lian,et al."Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation via the E2F3-dependent mechanism.".THERANOSTICS 12..1(2022):379-395